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INTRODUCTION 
Daidzein is an important isoflavone that is commonly 
found in soya beans and their derivative foods and 
produces several biological effects including significant 
improvement in endothelial function that may lead to 
protective cardiovascular effects, as suggested by 
findings from both experimental and clinical studies 
1,2,3,4,5)
. Some of the cardiovascular effects produced by 
this isoflavone include inhibition of platelet 
aggregation
6,7
, arterial vasorelaxation by nitric oxide 
dependent mechanisms 
8
, and enhanced vasodilatation in 
response to acetylcholine, as previously shown in aorta 
from spontaneously hypertensive rats.  
In agreement with these findings, increased soya 
isoflavone intake has been associated with significant 
reductions in arterial pressure, both in animal studies 
9,10
 
and in clinical trials
11
. Although mounting evidence 
indicates that daidzein produces antihypertensive and 
protective cardiovascular effects, the mechanisms 
underlying such beneficial effects are still poorly known. 
Angiotensin converting enzyme (ACE), a peptidyl 
dipeptidase enzyme, is a main regulator of the renin-
angiotensin system, which controls numerous important 
functions of the cardiovascular system. Indeed, ACE is 
liable for the conversion of relatively in active ACE-I to 
the potent vasoconstrictor ACE-II, which is the major 
product of the activation of the renin-angiotensin system 
12
 and a main controller of plasma volume, blood 
pressure, and sympathetic nervous activity. Although 
ACE-II can be generated by other enzymatic pathways, it 
has been broadly acknowledged that agents with ACE 
inhibiting properties produce valuable pharmacological 
and clinical effects 
13
.  
It is known that the plant-derived estrogens daidzein and 
daidzein have beneficial effects on serum lipids 
14
, 
however, no previous study has examined in this regard 
whether daidzein inhibits the vascular responses to ACE 
or increases the responses to bradykinin. Therefore the 
aim of the present study was to examine whether 
daidzein inhibits the in vivo responses to ACE-I or 
enhances the responses to bradykinin in anaesthetized 
rats as a result of ACE inhibition.  
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ABSTRACT: 
Daidzein produces antihypertensive and beneficial cardiovascular effects, although the mechanisms for these effects are not 
known. We examined whether genistein inhibits the in vivo responses to angiotensin I or enhances the responses to bradykinin 
in anaesthetized rats as a result of angiotensin-converting enzyme inhibition. We have also studied the in vitro effects produced 
by genistein on the angiotensin-converting enzyme activity. We measured the changes in systemic arterial pressure induced by 
angiotensin I in doses of 0.05 to 10 µg/kg, by angiotensin II in doses of 0.025 to 5 µg/kg, and to bradykinin in doses of 0.03 to 
10 µg/kg in anaesthetized rats pretreated with vehicle (controls), or a single i.v. dose of daidzein 25 mg/kg, or daily daidzein 25 
mg/kg i.v for two days, or a single i.v. dose of enalapril 2 mg/kg. Plasma angiotensin-converting enzyme activity was 
determined in controls and daidzein-treated rats using a fluorometric method. The effects of genistein (3–300 µmol/l) on in 
vitro angiotensin-converting enzyme activity were assessed by adding daidzein to plasma samples and measuring angiotensin-
converting enzyme activity. We found significant lower angiotensin-converting enzyme activity in plasma samples from rats 
pretreated with daidzein compared with those found in the control group (84.23±7.4 his-leu nmol/min/ml and 100.45±9.2 his-
leu nmol/min/ml, respectively; P = 0.01). The incubation of daidzein with plasma samples showed that daidzein decreased the 
angiotensin-converting enzyme activity in plasma in a concentration-dependent manner (P=0.01). These findings indicate that 
daidzein inhibits the angiotensin-converting enzyme in vivo and in vitro and may explain, at least in part, the antihypertensive 
and beneficial vascular effects produced by daidzein. 
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We have also studied the in vitro inhibitory effects 
produced by daidzein on the ACE activity. ACE 
inhibitors exert beneficial effects on both the heart and 
the kidney; its effects on cardiac parameters were 
measured as well to investigate variation in cardiac 
therapy response. 
MATERIALS AND METHODS 
Animals and treatments 
Male healthy Wistar rats (9 weeks old, 150-165g) were 
obtained from animal centre of Pretox Research Centre, 
Sachin, Surat, Gujarat, India. The rats were housed in 
plastic cages under identical conditions (12/ 12 hours 
light /dark cycle), in environmentally controlled rooms 
(22±3
0
C temperature, 50±20% relative humidity), 
including free access to both food (standard rat chow) 
and tap water. Animal care and treatment were 
conducted in compliance with Committee for the 
Purpose of Control and Supervision on Experiments on 
Animals (CPCSEA) guidelines. The experimental 
protocol was approved by the institutional animal ethics 
committee (IAEC protocol no.PRC/AFC/2013/037) of 
Pretox Research Centre, Sachin, Surat, Gujarat, India  
They were allowed for acclimation under climate-
controlled conditions for a week before use. We 
compared survival in all groups throughout the 
treatment. All animals were carefully monitored, and 
the number of dead rats was recorded every day. 
The rats were divided into three experimental groups. A 
first group was assigned to assess the arterial pressure 
responses to ACE-I, ACE-II, and bradykinin after a 
single dose of daidzein. The rats received vehicle (200 
µl of dimethyl sulfoxide) or daidzein (25 mg/kg) 
(n=5/group) via their femoral veins and then dose–
response curves to ACE-I, ACE-II, and bradykinin were 
evaluated immediately as described below. A second 
group was assigned to assess the arterial pressure 
responses against same peptides after double doses of 
daidzein. The rats (n=8/group) were treated for two 
days with daily i.v. injections of vehicle (200 µl of 
dimethyl sulfoxide) or daidzein (25 mg/kg) via their 
femoral veins and then dose–response curves to ACE-I, 
ACE-II, and bradykinin were recorded 2 hours after the 
second dose of daidzein as described below. Finally, a 
third or last group was designed to evaluate the pressure 
responses against peptides after a single dose of 
enalapril, as a positive control of daidzein. The rats 
(n=5/group) received vehicle (200 µl of saline) or 
enalapril (2 mg/kg) via their femoral veins and then 
dose-response curves to ACE-I, ACE-II, and bradykinin 
were evaluated as described below. 
The dose of daidzein was chosen with basis on a 
previous study daidzein
15
 showing significant inhibitory 
effects on plasma ACE activity. The dose of enalapril 
was based on previous study 
16
. The control animals 
received the same volumes of vehicle (200 µl) as 
compared with those infused in treated animals. 
At the end of experiments of the second group, blood 
samples were collected from rats treated with two doses 
of daidzein (or vehicle) to evaluate ACE activity. 
Preparation of animal for vascular responses 
On the day of surgery rats were anesthetized with 
ketamine injection (40 mg/kg, i.p.) and the trachea was 
cannulated carefully with a help of polyethylene tube 
(PE200) 
17
. A polyethylene catheter (PE50) was 
surgically inserted into the left carotid and the systemic 
blood pressure was recorded using a data acquisition 
system (Power Lab Systems, ADinstrument) connected 
to a computer. For i.v injection of drugs another 
polyethylene catheter (PE50) was canulated into the 
right femoral vein rats. The absence of somatic motor 
reflexes in response to tail pitching or blinking in 
response to a low pressure corneal stimulation indicated 
deep anesthesia and analgesia. At least 15 min of 
stabilization was allowed before drug infusions. 
Preparation of drug and solution 
All drugs and reagents used were purchased from 
Sigma Chemical Co. (USA). Standard daidzein was a 
kind gift from Sahajanand Medical Technologies Pvt 
Ltd, Surat, India. Daidzein was dissolved in dimethyl 
sulfoxide. ACE-I, ACE-II, and bradykinin were 
dissolved in saline solution immediately before use. 
Dose response curves to ACE-I, ACE-II, and 
bradykinin 
All drugs were dissolved in saline and were given in a 
100 µl intravenous bolus. After baseline assessment of 
mean arterial pressure and heart rate for 25 min, all rats 
received saline followed by ACE-I in doses of 0.05, 0.1, 
0.5, 1, 5, and 10 µg/kg, followed by ACE-II in doses of 
0.025, 0.05, 0.1, 0.5, 1, and 5 µg/kg, and then 
bradykinin in doses of 0.03, 0.1, 0.5, 1, 5, and 10 µg/kg. 
These doses were chosen with basis on previous studies 
18
 and in pilot studies. The changes in mean arterial 
pressure were calculated as the difference between the 
baseline value and those recorded at the highest values 
of mean arterial pressure after each dose of ACE-I or 
ACE-II, and as the difference between the baseline 
value and those recorded at the lowest values of mean 
arterial pressure after each dose of bradykinin. Each 
dose of drug was given when the mean arterial pressure 
had returned to baseline after the previous injection 
(usually 3–6 min) and real time mean arterial pressure 
recordings were carried out throughout the experiments. 
Effects of daidzein on plasma angiotensin-converting 
enzyme activity 
Plasma ACE activity of daidzein was assessed using a 
fluorometric method that measures the hydrolysis of the 
synthetic substrate hippuryl-His-Leu, as previously 
described 
19. Briefly, 5 μl of plasma samples were 
incubated with 245 μl of assay solution containing 5 
mM hippuryl-His-Leu in 0.4 M sodium borate buffer, 
pH 8.3, and 0.9 M NaCl for 15 min at 37°C. The 
reaction was stopped by adding 600 μl of 0.34 M 
NaOH. The product of this hydrolysis (His-Leu) was 
measured fluorometrically (365 nm excitation and 495 
nm emission) after the addition of 50 μl of o-
phthalaldehyde (20 mg/ml in methanol), which was 
followed 10 min later by the addition of 100 μl of 3 M 
HCl, and centrifugation at 800×g for 5 min. A standard 
curve was obtained with His-Leu (0.1–30 μM), which 
produced a linear relationship of relative fluorescence 
and His-Leu concentrations (data not shown) 
20
. 
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Enalapril (Sigma Chemical Co., USA) 0.1 mM was 
used as a positive control for this assay.  
Effects of daidzein on in vitro angiotensin-
converting enzyme activity 
To examine the effects of daidzein on in vitro 
angiotensin converting enzyme activity, we added 
daidzein (from 3 to 300 µmol/l) to plasma samples from 
rats and measured plasma angiotensin-converting 
enzyme activity as described above. These 
concentrations were based on previous studies showing 
that such concentrations inhibit angiotensin converting 
enzyme activity in rat aortic endothelial cells 
21
. In 
addition, the concentrations range studied here contain 
the plasma daidzein levels measured in clinical and 
experimental studies 
22, 23
. 
Drugs and solutions  
All drugs and reagents used were purchased from 
Sigma Chemical Co. (USA). Daidzein was dissolved in 
dimethyl sulfoxide. ACE-I, ACE-II, and bradykinin 
were dissolved in saline solution immediately before 
use. 
STATISTICAL ANALYSIS 
The results are expressed as means ± standard 
deviation. Comparisons of hemodynamic data between 
the groups were calculated by two-way analysis of 
variance (ANOVA) followed by Bonferroni post test. 
The between groups differences in plasma ACE 
activities were assessed by unpaired Student’s‘t’ test. 
One way analysis of variance followed by the Dunnet's 
test was used to analyze in vitro effects produced by the 
different concentrations of daidzein. A probability value 
< 0.05 was considered significant. 
RESULTS 
We found no significant differences in body weight, 
mean arterial pressure, and heart rate responses among 
the groups of rats studied here (all P>0.05, data not 
shown). Table 1 shows these parameters in rats treated 
with vehicle (controls) or daidzein for two days. 
 
Table 1 Body weight (BW), mean arterial pressure (MAP) and heart rate (HR) in anesthetized rats treated with vehicle 
(Control) or Daidzein. 
 
 
5.3.1 Effects of daidzein on vascular responses to 
angiotensin I, angiotensin II, and bradykinin  
To assess the outcomes of daidzein on ACE activity in 
vivo, we measured the changes in systemic arterial 
pressure induced by increasing doses of ACE-I, ACE-II, 
and bradykinin in anesthetized rats pretreated with 
vehicle, or after a single dose of daidzein, or after two 
doses of daidzein. Figure no. 1 shows the changes in 
systemic arterial pressure induced by ACE-I in doses of 
0.05 to 10 µg/kg (panels A and D) and by ACE-II in 
doses of 0.025 t o 5 µg/kg (panels B and E), respectively. 
While the pretreatment with daidzein significantly 
reduced the hypertensive responses induced by ACE-I in 
doses of 1, 3, and 10 µg/kg (Figure no. 1 A; P <0.05), 
this drug produced no significant effects on the 
hypertensive responses induced by ACE-II (Figure no. 
1B and E; P>0.05). In addition, the pretreatment with 
Daidzein produces antihypertensive and beneficial 
cardiovascular effects, although the mechanisms for 
these effects are not known. We examined whether 
genistein inhibits the in vivo responses to angiotensin I 
or enhances the responses to bradykinin in anaesthetized 
rats as a result of angiotensin-converting enzyme 
inhibition. We have also studied the in vitro effects 
produced by genistein on the angiotensin-converting 
enzyme activity. We measured the changes in systemic 
arterial pressure induced by angiotensin I in doses of 
0.05 to 10 µg/kg, by angiotensin II in doses of 0.025 to 5 
µg/kg, and to bradykinin in doses of 0.03 to 10 µg/kg in 
anaesthetized rats pretreated with vehicle (controls), or a 
single i.v. dose of daidzein 25 mg/kg, or daily daidzein 
25 mg/kg i.v for two days, or a single i.v. dose of 
enalapril 2 mg/kg. Plasma angiotensin-converting 
enzyme activity was determined in controls and 
daidzein-treated rats using a fluorometric method. The 
effects of genistein (3–300 µmol/l) on in vitro 
angiotensin-converting enzyme activity were assessed by 
adding daidzein to plasma samples and measuring 
angiotensin-converting enzyme activity. We found 
significant lower angiotensin-converting enzyme activity 
in plasma samples from rats pretreated with daidzein 
compared with those found in the control group 
(84.23±7.4 his-leu nmol/min/ml and 100.45±9.2 his-leu 
nmol/min/ml, respectively; P = 0.01). The incubation of 
daidzein with plasma samples showed that daidzein 
decreased the angiotensin-converting enzyme activity in 
plasma in a concentration-dependent manner (P=0.01). 
These findings indicate that daidzein inhibits the 
angiotensin-converting enzyme in vivo and in vitro and 
may explain, at least in part, the antihypertensive and 
beneficial vascular effects produced by daidzein. 
 daidzein significantly increased the hypotensive 
responses induced by bradykinin in doses of 0.3, 1, 5, 
and 10 µg/kg (Figure no. 1C and F;P< 0.05). As a 
positive control, animals that received a single dose of 
enalapril (2 mg/kg) showed significantly lower 
Sr. No Parameters Control (vehicle) 
Daidzein 
25 mg/kg 
P value 
1 Body weight 254  ±8.5 249 ±9.2 NS 
2 Mean arterial pressure 100±5.8 103±4.5 NS 
3 Heart rate 360±12.2 392±11.2 NS 
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hypertensive responses to angiotensin I (Figure no. 1G; 
P>0.05), increased hypotensive responses to bradykinin 
(Figure no. 1H; P>0.05), and no significant changes in 
the hypertensive responses induced by angiotensin II 
(Figure no. 1I; P>0.05). 
 5.3.2 Daidzein inhibits in vitro angiotensin-
converting enzyme activity  
We found significant lower angiotensin-converting 
enzyme activity in plasma samples from rats pretreated 
with daidzein compared with those found in plasma 
samples from rats in the Control group (84.23±7.4 his-
leu nmol/min/ml and 100.45±9.2 his-leu nmol/min/ml, 
respectively; P=0.01; Figure no. 2A). In addition, the 
incubation of daidzein (10 to 300 μM) with a pool of 
plasma samples from rats showed that daidzein 
decreased the angiotensin converting enzyme activity in 
plasma in a concentration-dependent manner (Pb<0.01; 
Figure no. 2B). 
 
      
Figure 1 A                                                            Figure1 B 
 
Figure 1 C                                                                        Figure 1 D 
 
Figure 1 E                                                                        Figure 1 F 
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Figure 1 G                                                                           Figure 1 H 
 
Figure 1 I                                                                                              
 
Figure no. 1. Change in systemic arterial blood pressure 
induced by the intravenous injections of saline and 
angiotensin I in doses of 0.03, 0.1, 0.3, 1, 3, and 10 
μg/kg, followed by angiotensin II in doses of 0.01, 0.03, 
0.1, 0.3,1, and 3 μg/kg, and then by bradykinin in doses 
of 0.03, 0.1, 0.3,1, 3, and 10 μg/kg in anesthetized 
animals treated with vehicle-control, or a single dose of 
daidzein (panels A, B and C), or two doses of daidzein 
(panels D, E and F) or single dose of captopril (panels G, 
H and I). Data are shown as mean±S.E.M; n=4 per group 
in panels A, B, and C; n=8 per group in panels D, E, and 
F; and n=4 per group in panels G, H, and I. *P<0.05, 
**P<0.01, ***P<0.001 versus the respective Control 
group. N.S. =non significant differences versus the 
respective Control group. 
Figure no. 2. Panel A shows plasma angiotensin 
converting enzyme (ACE) activity in vehicle (Control) or 
after treatment with daidzein for two days. Angiotensin 
converting enzyme activity was assessed using a 
fluorometric method with the use of Hippuryl- His-Leu 
as substrate. Panel B shows daidzein induced inhibition 
of angiotensin converting enzyme (ACE) activity in 
vitro. A pool of plasma samples from rats was treated 
with captopril 0.1 mM, vehicle, or daidzein 3, 10, 30, 
100, and 300 μM. Data are shown as mean±S.E.M of at 
least three independent experiments performed in 
triplicate. P=0.01 (Daidzein versus the Control group). 
***P<0.001 versus the Control group. 
 
Figure 2                                                             Figure 2 B 
Choudhury et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(6):92-98 97 
© 2011-14, JDDT. All Rights Reserved                                      ISSN: 2250-1177                                    CODEN (USA): JDDTAO 
 
DISCUSSION AND CONCLUSION 
The major outcomes of this study were: (a) Daidzein 
pretreatment reduced the hypertensive responses 
persuaded by substance known as angiotensin I, and 
raised the hypotensive responses provoked by bradykinin 
without considerably modifying the responses to 
angiotensin II after two days of treatment; (b) these 
hemodynamic upshots were allied with significant 
decrease in activity of angiotensin converting enzyme in 
sample of plasma from rats pretreated with daidzein for 
two days compared with plasma of control group rats; (c) 
inhibitory action produced by daidzein in vivo on the 
angiotensin converting enzyme activity were 
corroborated with in vitro studies. Taken together, these 
data show daidzein produces relevant hemodynamic 
modifications and prove previous findings signifying that 
daidzein inhibits the ACE activity 
21
. 
Daidzein have various biological activities which is 
proved by several studies 
2
. These actions comprise 
beneficial vascular alterations in humans 
24
 and 
diminution in arterial blood pressure in animal models of 
hypertension. In fact, even though daidzein lowered the 
BP in spontaneously hypertensive rats 
2, 3 
and attenuated 
the hypertensive effects of dietary NaCl in hypertensive 
animals 
25
, the precise mechanisms for these 
antihypertensive effects are poorly understood. 
Importantly, Xu et al. 
15
 elegantly demonstrated for the 
first time that daidzein could inhibit the ACE activity in 
vitro as well as in plasma and tissues of rats via reduction 
of angiotensin-converting enzyme expression of the 
angiotensin converting enzyme 
15
. On the other hand, no 
study has previously evaluated whether the inhibition of 
the angiotensin converting enzyme activity by daidzein 
could create relevant hemodynamic action in vivo, as we 
have shown in the present study. 
The reduction in the responses to angiotensin I and the 
enhanced responses to bradykinin reported here, which 
were associated with lower ACE activity in vivo and in 
vitro, inflates earlier outcomes reported by Xu et al. 
15
, 
The outcomes of this study show that, additionally to the 
inhibition of ACE expression, daidzein can inhibit 
angiotensin- converting enzyme activity in such a way 
that relevant hemodynamic modifications are produced. 
Actually, the angiotensin converting enzyme is a key 
enzyme regulating the rennin angiotensin aldosterone 
system (RAAS), and plays a vital role in the regulation 
of blood pressure and cardiovascular function.  
The outcome of this study helps to explain how daidzein 
produced antihypertensive effects in earlier experiments 
2, 3, 25
 using special models of hypertension. It would be 
interesting to examine the effects produced by daidzein 
on the angiotensin-converting enzyme expression and 
activity in different animal models of hypertension, 
especially in those with activated RAAS. 
In conclusion, our findings show that daidzein reduced 
the hypertensive responses induced by angiotensin I, 
enhanced the hypotensive responses to bradykinin, and 
inhibited the angiotensin converting enzyme activity in 
plasma, both in vivo and in vitro. These findings indicate 
that daidzein inhibits the angiotensin converting enzyme 
and may explain, at least in part, the antihypertensive and 
beneficial vascular effects produced by daidzein. 
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